Message

From: Miquelon, Wade [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=WALGREENS.ONMICROSOFT.COM-54052-MIQUELON, WADE D. (WMIQF7F8C9A1]
Sent: 3/25/2014 9:59:57 PM
To: Kohli, Ashish [ashish.kohli@walgreens.com]
CC: Hans, Rick [rick.hans@walgreens.com]
Subject: Re: Theranos

Project is going well. When we have a new milestone to share we will share it. Wade

> On Mar 25, 2014, at 4:53 PM, "Kohli, Ashish" <ashish.kohli@walgreens.com> wrote:
>
> Wade,
>
> Hope you are feeling better. How would you like me to respond?
>
> Thanks,
> Ashish
>
> Ashish Kohli, CFA
> Director, Investor Relations
> Office: 847.315.3810
> ashish.kohli@walgreens.com
>
>
>
>
>
>
>
>
>> On 3/25/14 4:31 PM, "Vivek Khanna" <Vivek@[redacted]> wrote:
>>
>> Ashish,
>>
>> I cannot help notice no mention of Theranos in the press release or in
>> the prepared comments. Is there a change in uptake or roll out schedule?
>>
>> Look forward to our call in the morning on exchanges.
>>
>> Thanks
>>
>> Vivek
>>
>>
>> _____
>> Messages sent to and from Partner Fund Management may be monitored. The
>> sender of this email is associated with an entity that trades in
>> securities. As a result, the sender does not wish to receive any
>> material, nonpublic information regarding a public company or information
>> provided in violation of any duty or obligation or any U.S. or non-U.S.
>> securities laws.
>> _____
>

CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO FED. R. CRIM. P. 6(e). This confidential document is provided to the U.S. Department of Justice in response to a grand jury subpoena, and neither the document nor its contents may be disclosed to any other person or entity except as authorized under Fed. R. Crim. P. 6(e).